Observational study of vaccination in cancer patients: How can vaccine coverage be improved?

Monier, Anna; Puyade, Mathieu; Hernanz, Maria Pilar Gallego; Bouchaert, P.; Leleu, Xavier; Tourani, Jean-Marc; Roblot, P.; Rammaert, Blandine

doi:10.1016/j.medmal.2019.11.006

Cited by 22 publications

(20 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is a need for increased awareness and education of the importance of receiving the annual influenza vaccination in immunocompromised individuals and healthcare workers [ 241 , 242 ]. Although it is highly recommended for many immunocompromised populations to get the influenza vaccine annually because of the increased risk of fatal conditions, these populations remain heavily under-vaccinated [ 243 , 244 ]. Immunocompromised individuals have higher rates of pneumonia and mortality from influenza and longer hospital stays than non-immunocompromised individuals [ 245 ].…”

Section: Immunocompromised Individualsmentioning

confidence: 99%

Review of Influenza Virus Vaccines: The Qualitative Nature of Immune Responses to Infection and Vaccination Is a Critical Consideration

Chan

Alizadeh

et al. 2021

Vaccines

View full text Add to dashboard Cite

Influenza viruses have affected the world for over a century, causing multiple pandemics. Throughout the years, many prophylactic vaccines have been developed for influenza; however, these viruses are still a global issue and take many lives. In this paper, we review influenza viruses, associated immunological mechanisms, current influenza vaccine platforms, and influenza infection, in the context of immunocompromised populations. This review focuses on the qualitative nature of immune responses against influenza viruses, with an emphasis on trained immunity and an assessment of the characteristics of the host–pathogen that compromise the effectiveness of immunization. We also highlight innovative immunological concepts that are important considerations for the development of the next generation of vaccines against influenza viruses.

show abstract

Section: Immunocompromised Individualsmentioning

confidence: 99%

Review of Influenza Virus Vaccines: The Qualitative Nature of Immune Responses to Infection and Vaccination Is a Critical Consideration

Chan

Alizadeh

et al. 2021

Vaccines

View full text Add to dashboard Cite

show abstract

“…17) In France, factors influencing pneumonia vaccination in patients diagnosed with cancer were examined, irrespective of the use of anticancer therapy, and the highest vaccination rate (12.9 times) was shown by the patients for whom the family doctor had provided vaccination information. 18) In the case of patients with PPSV23 vaccination history prior to the first visit (data not shown), not a single patient from the B, or the B+Br group received the vaccination.…”

Section: )mentioning

confidence: 94%

Impact of a Doctor's Verbal Recommendation on Pneumococcal 13-Valent Conjugate Vaccine among High-Risk Patients for Pneumonia in a Primary Care Setting

김지한¹,

Lee²,

Kim³

2021

KJHP

View full text Add to dashboard Cite

Background: Streptococcus pneumoniae is the main bacterial pathogen of community-acquired pneumonia in Korea. This study aimed to enhance the vaccination rate by evaluating the effectiveness of current methods of recommendation.Methods: A retrospective analysis of the medical records of 143 patients with high risk of pneumonia among first-visit outpatients was conducted. High-risk patients for pneumonia are defined by the U.S. Advisory Committee on Immunization Practices. One hundred and twenty-seven patients, excluding 16 with pneumococcal 13-valent conjugate vaccination (PCV13) history prior to the first visit, were divided into three groups according to the method of vaccination recommendation: banner (B) group; banner+brochure (B+Br) group; banner+brochure+doctor's recommendation (B+Br+DR) group. The vaccination rates among patients in each group were compared.Results: Patients with high risk of pneumonia showed 11.2% rate for PCV13 vaccination upon their first visit;however, this rate increased to 39.2% following counseling (P<0.001). Variation among the three groups was as follows: 9.0% in the B group, 20.0% in the B+Br group, and 75.0% in the B+Br+DR group (P<0.001). After adjusting for age, sex, high-risk group, occupation, and residence, a regression analysis was carried out. The odds ratio for the PCV13 vaccination rate compared to the B group was 2.49 (95% confidence interval [CI], 0.55-11.34) for the B+Br group and 43.72 (95% CI, 11.52-165.96) for the B+Br+DR group.Conclusions: Among the available methods, we are thought to be more effective to add doctor's verbal recommendation in a clinical setting.

show abstract

“…В последнее время отмечается увеличение количества пациентов, получающих таргетные лекарственные средства, моноклональные антитела и новые агенты при лечении аутоиммунных, ревматологических заболеваний и злокачественных новообразований. Важно отметить, что инвазивные пневмококковые инфекции обычно протекают более тяжело в обозначенных группах высокого риска в сравнении с общей популяцией иммунокомпетентных лиц [1][2][3][4][5].…”

Section: Introductionunclassified

Clinical and Immunological Aspects of Pneumococcal Vaccination in Patients with Multiple Myeloma

Stoma

2021

Epidemiology and Vaccinal Prevention

View full text Add to dashboard Cite

Relevance. Among the groups at high risk of developing invasive pneumococcal infections, patients with multiple myeloma (MM) stand out among the highest rates of morbidity and mortality due to the presence of profound immunosuppression. Aims: to outline the current state of the problem of vaccine prevention of pneumococcal infection in patients receiving treatment for multiple myeloma, to present the evidence base for vaccination with conjugated pneumococcal vaccine. A continuous data review method was used to evaluate the studies on vaccination approaches against pneumococcal infection in patients with multiple myeloma. Conclusions. The article presents modern epidemiological data, as well as the results of original studies of clinical and immunological aspects of pneumococcal vaccination in patients with MM receiving new targeted agents and immunotherapy. The effectiveness of the use of the conjugated pneumococcal vaccine in patients treated with MM with bortezomib, lenalidomide, and ixazomib was indicated. An independent protective effect of pneumococcal vaccination has been shown as a preventive measure in a cohort of patients with MM, against the background of treatment with new targeted drugs.

show abstract

Observational study of vaccination in cancer patients: How can vaccine coverage be improved?

Cited by 22 publications

References 23 publications

Review of Influenza Virus Vaccines: The Qualitative Nature of Immune Responses to Infection and Vaccination Is a Critical Consideration

Review of Influenza Virus Vaccines: The Qualitative Nature of Immune Responses to Infection and Vaccination Is a Critical Consideration

Impact of a Doctor's Verbal Recommendation on Pneumococcal 13-Valent Conjugate Vaccine among High-Risk Patients for Pneumonia in a Primary Care Setting

Clinical and Immunological Aspects of Pneumococcal Vaccination in Patients with Multiple Myeloma

Contact Info

Product

Resources

About

Observational study of vaccination in cancer patients: How can vaccine coverage be improved?

Cited by 22 publications

References 23 publications

Review of Influenza Virus Vaccines: The Qualitative Nature of Immune Responses to Infection and Vaccination Is a Critical Consideration

Review of Influenza Virus Vaccines: The Qualitative Nature of Immune Responses to Infection and Vaccination Is a Critical Consideration

Impact of a Doctor&apos;s Verbal Recommendation on Pneumococcal 13-Valent Conjugate Vaccine among High-Risk Patients for Pneumonia in a Primary Care Setting

Clinical and Immunological Aspects of Pneumococcal Vaccination in Patients with Multiple Myeloma

Contact Info

Product

Resources

About

Impact of a Doctor's Verbal Recommendation on Pneumococcal 13-Valent Conjugate Vaccine among High-Risk Patients for Pneumonia in a Primary Care Setting